Cost–benefit of the introduction of new strategies for vaccination against pertussis in Spain: Cocooning and pregnant vaccination strategies

Fernández-Cano, María Isabel; Gil, Lluı́s; Campins-Martí, Magda

doi:10.1016/j.vaccine.2015.03.045

Cited by 28 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 Fernández estimated that the MV was more favorable than cocoon strategy in number needed to vaccinate (NNV) and in cost/benefit in Spanish population. 42 However, Lugnér studied the sensitivity in the Netherlands and compared the cost-effectiveness of three infant protection strategies against pertussis: infant vaccination in the first two months, MV and PMV, the last one had a more attractive ICER, 890.00 EUR/QALY with annual cost of 1.8 million. 9 The MV had 126.000 EUR/QALY and annual cost of three million Euros.…”

Section: Security and Cost/effectivenessmentioning

confidence: 99%

“…12 In the Spanish population, the cost of vaccination to prevent death is much greater with the cocoon strategy than with the MV: EUR 15.783.648 compared with EUR 3.461.326, respectively. 42 In 2011 the Center for Disease Control [CDC] and Prevention's Advisory Committee on Immunization Practices [ACIP] recommended Tdap to pregnant women who previously had not received it; in 2013 it was extended to each pregnancy, independent of the previous vaccination and between 27-36 weeks of gestation (1,43). 49 Similarly, the entities indicated to avoid previous recommendations about the use of PMV.…”

Section: Security and Cost/effectivenessmentioning

confidence: 99%

See 1 more Smart Citation

Benefits of maternal vaccination to prevent pertussis in infants

Monterrosa-Castro

Ramirez-García

Beltrán-Barrios

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Pertussis, also called whooping cough, is an infectious and preventable pathology that generates important child morbidity and mortality worldwide. There are different biological preparations for its use in infants, while for adolescents and adults is Tdap, (acellular vaccine of purified extracts of Bordetella pertussis (BP), combined with tetanus and diphtheria toxoid) that has been proposed as maternal vaccination (MV). The objective was to identify the benefits of MV in the prevention of childhood pertussis, a review was made in PubMed, Science Direct, EBSCOhosT, OvidSP and Embase databases (years 2008-2016) and an electronic alert system (January-April 2017). 1083 titles were identified and 44 articles were selected. After the MV (administered between 27 and 36 weeks of gestation) the passage of IgG-BP to the fetus is sufficient to generate adequate infant protection, generating two benefits: reducing infant morbidity (number of cases and hospital admissions) and decreasing mortality by pertussis. The MV offers 93% of effectiveness [95%CI: 81-97] and OR: 0.09 [95%CI: 0,03-0,25]. The MV is more favorable in each pregnancy than cocoon strategy, vaccination before pregnancy, before 26 weeks of gestation or in the postpartum. The use of MV is a safe and cost-effectiveness tool to prevent childhood pertussis.

show abstract

Section: Security and Cost/effectivenessmentioning

confidence: 99%

Section: Security and Cost/effectivenessmentioning

confidence: 99%

Benefits of maternal vaccination to prevent pertussis in infants

Monterrosa-Castro

Ramirez-García

Beltrán-Barrios

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…2 In case-control and surveillance studies in the UK, maternal vaccination prevented 91 and 93% of laboratory-confirmed pertussis cases in infants <3 months old. 12–14 Economic studies typically focused on prevention of pertussis in infants alone, 15–17 as they are at greatest risk of severe consequences. However, important clinical and economic gains achieved from direct protection of mothers are often overlooked.…”

Section: Introductionmentioning

confidence: 99%

Is adding maternal vaccination to prevent whooping cough cost-effective in Australia?

Bellinghen

Dimitroff

Haberl

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Pertussis or whooping cough, a highly infectious respiratory infection, causes significant morbidity and mortality in infants. In adolescents and adults, pertussis presents with atypical symptoms often resulting in under-diagnosis and under-reporting, increasing the risk of transmission to more vulnerable groups. Maternal vaccination against pertussis protects mothers and newborns. This evaluation assessed the cost-effectiveness of adding maternal dTpa (reduced antigen diphtheria, Tetanus, acellular pertussis) vaccination to the 2016 nationally-funded pertussis program (DTPa [Diphtheria, Tetanus, acellular Pertussis] at 2, 4, 6, 18 months, 4 years and dTpa at 12–13 years) in Australia.A static cross-sectional population model was developed using a one-year period at steady-state. The model considered the total Australian population, stratified by age. Vaccine effectiveness against pertussis infection was assumed to be 92% in mothers and 91% in newborns, based on observational and case-control studies. The model included conservative assumptions around unreported cases.With 70% coverage, adding maternal vaccination to the existing pertussis program would prevent 8,847 pertussis cases, 422 outpatient cases, 146 hospitalizations and 0.54 deaths per year at the population level. With a 5% discount rate, 138.5 quality-adjusted life-years (QALYs) would be gained at an extra cost of AUS$ 4.44 million and an incremental cost-effectiveness ratio of AUS$ 32,065 per QALY gained. Sensitivity and scenario analyses demonstrated that outcomes were most sensitive to assumptions around vaccine effectiveness, duration of protection in mothers, and disutility of unreported cases.In conclusion, dTpa vaccination in the third trimester of pregnancy is likely to be cost-effective from a healthcare payer perspective in Australia.

show abstract

“…10 Bu nedenle 2000'li yılların ortası itibarıyla gelişmiş ülke-lerde adölesanlara, gebelere ve tüm erişkinlere bir pekiştirme doz tetanos ve difteri toksoidi ile kombine aP aşısının (TdaP) yapılması önerilmekte-dir. 1,2,11,12 Ülkemizde de erişkin dönemde yapılacak pekiştirme dozlarından birinin TdaP olması, ayrıca 19 yaş ve üzeri erişkinler için her 10 yılda bir pekiştirme doz Td/TdaP aşısının erişkin aşı takvimine eklenmesi önerilmektedir. 6 DSÖ'ye üye 194 ülkenin 129'unda DTaP aşı-lama hızı %90'ın üzerindedir.…”

unclassified

“…Ayrıca, bebeklerde epidemilerin yaygınlığı boğmaca aşı programlarının çoğunlukla ikinci aydan sonra baş-laması ve aşılanan bebeklerde dördüncü doza kadar yeterli antikor titresi oluşmaması ile ilişkilendiril-mektedir. 2,9,12,16,[18][19][20] Amerika Birleşik Devletleri (ABD)'nde 2010 yılındaki boğmaca epidemisinde, boğmaca vakalarının %70'ten fazlasının altı aydan küçük çocuklar olduğu, hospitalizasyon ve ölüm oranlarının üç aydan küçük bebeklerde daha yük-sek olduğu saptanmıştır. 21,22 ABD'de 2015 yılında rapor edilen 20.762 boğmaca vakasının %9,5 (1.970 vaka)'inin altı aydan küçük çocuklar olduğu bildirilmiştir.…”

unclassified

A Different Approach to Pertussis Immunization: Cocooning Strategy

Terzi¹,

Kıtış²

2018

Turkiye Klinikleri J Nurs Sci

View full text Add to dashboard Cite

Cost–benefit of the introduction of new strategies for vaccination against pertussis in Spain: Cocooning and pregnant vaccination strategies

Cited by 28 publications

References 27 publications

Benefits of maternal vaccination to prevent pertussis in infants

Benefits of maternal vaccination to prevent pertussis in infants

Is adding maternal vaccination to prevent whooping cough cost-effective in Australia?

A Different Approach to Pertussis Immunization: Cocooning Strategy

Contact Info

Product

Resources

About